Vitae Pharmaceuticals, Inc., a pharmaceutical company, engages in discovering, developing, and commercializing small molecule drugs. Its products include renin inhibitors for the management of hypertension and end-organ protection, inhibitors for the treatment of diabetes, novel oral anti-inflammatory agents for the treatment of Rheumatoid Arthritis, and orally active inhibitors for the treatment of Alzheimer's disease. The company’s products target various therapeutic categories, including cardiovascular, metabolic, inflammation, cancer, and CNS diseases. It has strategic alliance with GlaxoSmithKline and Intel. The company was formerly known as Concurrent Pharmaceuticals, Inc. and changed its name to Vitae Pharmaceuticals, Inc. in January 2005. The company was founded in 2002 and is headquartered in Fort Washington, Pennsylvania.